Rudacure

Rudacure is a South Korean biotechnology company dedicated to developing first-in-class therapeutics for sensory system diseases, particularly in the fields of ophthalmology and chronic pain. The company's lead asset, RCI001, is a novel small molecule treatment for dry eye syndrome that has demonstrated potent anti-inflammatory and corneal healing properties in clinical studies. Rudacure leverages its proprietary Ruda-Platform to identify drug candidates that modulate ion channels and other key signaling pathways involved in sensory perception. In addition to its ophthalmic pipeline, the company is advancing programs for neuropathic pain and inflammatory itch, with a focus on targeting the TRPV1 receptor. Through collaborations with established pharmaceutical partners like Hanlim Pharm, Rudacure is positioned to transition its research into late-stage clinical development and commercialization. The company is headquartered in the Songdo Bio Cluster in Incheon, South Korea.